Bristol-Myers Squibb BMY Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $7.06B+178% | -$9.01B-212% | $8.04B+26.7% | $6.35B-9.5% | ||
| $4.01B-58.2% | $9.6B-1.6% | $9.76B-5.0% | $10.28B-3.8% | ||
| $553M+9.1% | $507M-2.1% | $518M+13.3% | $457M-21.6% | ||
| -$965M+53.8% | -$2.09B+36.5% | -$3.29B-20.1% | -$2.74B-96.6% | ||
| —— | —— | $751M+988% | $69M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$4M+99.7% | -$1.38B— | —— | -$1.48B-39.5% | ||
| —— | -$264M-127% | $995M+50.1% | $663M-37.1% | ||
| $14.16B-6.8% | $15.19B+9.6% | $13.86B+6.1% | $13.07B-19.4% | ||
| $1.31B+5.0% | $1.25B+3.2% | $1.21B+8.1% | $1.12B+14.9% | ||
| $3.94B-81.9% | $21.82B+1,767% | $1.17B-72.7% | $4.29B+166% | ||
| -$4.13B+80.6% | -$21.35B-830% | -$2.3B— | —— | ||
| $5.05B+3.7% | $4.86B+2.5% | $4.74B+2.4% | $4.63B+5.4% | ||
| $10.94B+281% | $2.87B-25.9% | $3.88B-66.1% | $11.43B+89.8% | ||
| -$10.35B— | —— | —— | -$16.96B-4.5% | ||
| $199M+245% | -$137M— | —— | —— | ||
| -$129M— | —— | $2.19B— | —— | ||
| $3.72B-72.2% | $13.37B+1,365% | $913M+12.0% | $815M-29.7% | ||
| $351M— | $0— | $0+100% | -$9M+98.3% | ||
| —— | $1.12B+26.6% | $884M-16.8% | $1.06B+55.4% | ||
| $1.1B-62.9% | $2.96B+1,062% | $255M+42.5% | $179M-85.2% | ||
| -$441M— | —— | —— | —— | ||
| -$232M— | —— | -$300M— | —— | ||
| —— | $1.1B+20.9% | $909M-30.3% | $1.31B+74.5% | ||
| $1.98B+76.0% | $1.12B+53.1% | $733M-88.6% | $6.41B+52.8% | ||
| $77M-70.9% | $265M+23.3% | $215M-1.4% | $218M-91.5% | ||
| -$139M— | —— | $27M-97.3% | $984M— | ||
| $0— | —— | —— | $0— | ||
| —— | —— | —— | $194M— | ||
| —— | —— | —— | $0— | ||
| $12.85B-7.9% | $13.94B+10.2% | $12.65B+5.9% | $11.95B-21.6% | ||
| $12.85B-7.9% | $13.94B+10.2% | $12.65B+5.9% | $11.95B-21.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bristol-Myers Squibb generate?
- Bristol-Myers Squibb (BMY) generated $13.3B in operating cash flow over the trailing twelve months.
- What is Bristol-Myers Squibb's free cash flow?
- After $1.4B of capital expenditures, Bristol-Myers Squibb's free cash flow was $11.9B over the trailing twelve months, down 9.0% year over year.
- Where does Bristol-Myers Squibb's cash flow data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
